Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
Our off-the-shelf, allogeneic T cells are bioengineered from donors with healthy immune function and allow for rapid delivery to patients.
Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s T-cell immunotherapies are designed to precisely recognize and target cancerous or diseased cells without affecting normal, healthy cells.
Atara’s off-the-shelf, allogeneic T-cell immunotherapy in development, tabelecleucel, or tab-cel® (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).
Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS).
